Monte Rosa Therapeutics, Inc. cotiza a 10.52 USD y tiene una capitalización bursátil de $897M. En los últimos 12 meses ha facturado $29M con un margen de flujo de caja libre del -22.2%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.43 | $-0.45 | $-0.55 |
| Estimado | $-0.20 | $-0.37 | $-0.38 | $-0.34 |
| Sorpresa | — | -16.2% | -18.4% | -61.8% |
| Métrica | GLUE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -43.8% | -38.6% | -5.2% |
| Net Margin | -31.2% | -33.6% | +2.3% |
| FCF Margin | -22.2% | -13.9% | -8.4% |
| ROE | -16.6% | -40.4% | +23.8% |
| ROA | -8.6% | -32.0% | +23.4% |
| Current Ratio | 6.12 | 2.84 | +3.28 |
| Debt / Equity | — | 0.28 | — |